CSL-Tox: an open-source analytical framework for the comparison of short-term and long-term toxicity end points and

Doha Naga1,2, Smaragda Dimitrakopoulou3,4, Sonia Roberts3

  • 1Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. dohanaga@gmail.com.

Scientific Reports
|September 8, 2023
PubMed

Insights

Short-term in-vivo toxicity studies can predict long-term effects for most new molecular entities, reducing animal use. This analysis supports minimizing long-term studies, aligning with the 3Rs principle.

Area of Science:

  • Preclinical toxicology
  • Drug development
  • Regulatory science

Background:

  • In-vivo toxicity assessment is crucial for new molecular entity (NCE) risk evaluation before clinical trials.
  • Regulatory requirements mandate in-vivo studies, with ongoing efforts to minimize animal use via the 3Rs principle (Replacement, Reduction, Refinement).
  • Optimizing study duration and number is key to reducing animal usage in toxicology packages.

Purpose of the Study:

  • To statistically compare adverse findings from short-term versus long-term in-vivo toxicity studies.
  • To explore the potential of short-term studies as predictive tools for long-term effects.
  • To support the minimization of long-term toxicity studies in drug development.

Main Methods:

  • Manual data extraction from 116 short-term and 78 long-term toxicology reports (PDF format).
  • Statistical comparison of adverse findings, with a focus on summary and conclusion sections for expert assessment.
  • Development of an open-source R workflow (CSL-Tox) for reproducible analysis.

Main Results:

  • Good concordance between short-term and long-term toxicity findings was observed for large molecules and most small molecules.
  • Lower concordance was noted for specific "target organ systems' findings".
  • The study provides evidence supporting the reduction of long-term toxicity studies.

Conclusions:

  • Short-term toxicity studies show promise in predicting long-term effects for many NCEs, aiding in animal use reduction.
  • Further large-scale studies are needed to solidify these findings and refine predictive models.
  • Emphasis on reproducible adverse effect reporting, controlled terminologies, and open-source workflows is vital for preclinical toxicology research.